Generation of Robust Resident Memory T cells in Barrier Tissues through Skin Vaccination
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3R01AI127654-05S1
Grant search
Key facts
Disease
COVID-19Start & end year
20212021Known Financial Commitments (USD)
$443,750Funder
National Institutes of Health (NIH)Principal Investigator
Thomas S Kupper, Rachael Ann ClarkResearch Location
United States of AmericaLead Research Institution
Brigham And Women'S HospitalResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
SUMMARY COVID 19, the lower respiratory disease caused by SARS CoV2v virus, is the latest betacoronavirus to cause epidemic disease in humans. Previously, SARS and MERS, both cause by related viruses, emerged and fell dormant as epidemics. Successful vaccines have been developed; however, they are likely to provide relatively narrow immunity based on antibodies to Spike (and attendant TFH cells) rather than T cell memory. Patients who have been infected by SARS CoV2 have more broad based immunity, but immunity to respiratory pathogens is relatively transient. We have developed MVA vaccines delivered by epidermal disruption to sequences of SARS CoV2 that are highly conserved, and have substantial evidence that the immunity generated by these vaccines will be durable and protective.